Nkarta Therapeutics

Nkarta Therapeutics

  • Founded: 2015
  • Location: South SF, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: AML , MDS
  • Drug types: ONC
  • Lead product: NKX101
  • Product link: https://www.nkartatx.com/pipeline/
  • Funding: $200M stock Apr 2022; $289.8M IPO Jul 2020; $114M B Sep 2019; $11M 2015
  • Investors: Samsara, NEA Ventures, SR One, Novo Holdings, Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management



job board

Short description:

Allogeneic cellular immunotherapy platform

Drug notes:

Also Clin0 multiple cancers; NKX019 Clin1 B cell malignancies; undisclosed RD oncology; undisclosed RD undisclosed

Long description:

Contact us to add description.


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com